临床试验/NCT00809510

NCT00809510终止2 期

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Abbott22 个研究点分布在 1 个国家目标入组 63 人开始时间: 2009年1月最近更新: 2011年9月2日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方: Abbott
入组人数: 63
试验地点: 22
主要终点: Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 55 Years 至 90 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•The subject was randomized into Study M06-876 and completed the study.
•The subject must remain on the same dose of AChEI that was used during the M06-876 study.
•The subject is in general good health, as judged by the investigator

排除标准

•The subject is currently, or plans to participate in another experimental study during the course of this trial.
•The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.

研究组 & 干预措施

1

Experimental

干预措施: ABT-089 (Drug)

结局指标

主要结局

Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)

时间窗: Month 1, 2, 4, 6

次要结局

ADAS-Cog, CIBIC-plus, MMSE, QoL-AD(Month 1, 2, 4, 6)

研究者

发起方

Abbott

申办方类型

Industry

责任方

Sponsor

研究点 (22)

Loading locations...

相似试验

已完成

2 期

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder

NCT00443391AbbVie (prior sponsor, Abbott)141

终止

2 期

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity Disorder

NCT00554385Abbott283

已完成

2 期

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity Disorder

NCT00686933AbbVie (prior sponsor, Abbott)117

终止

2 期

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's Disease

NCT01676935AbbVie (prior sponsor, Abbott)349

终止

2 期

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's Disease

NCT01690195AbbVie (prior sponsor, Abbott)343